California Public Employees Retirement System reduced its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 4.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,200 shares of the biopharmaceutical company’s stock after selling 3,100 shares during the period. California Public Employees Retirement System owned approximately 0.07% of Juno Therapeutics worth $1,580,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new stake in shares of Juno Therapeutics during the fourth quarter worth approximately $204,000. Norges Bank bought a new position in shares of Juno Therapeutics during the fourth quarter worth about $13,993,000. Teachers Advisors LLC increased its position in shares of Juno Therapeutics by 12.3% in the fourth quarter. Teachers Advisors LLC now owns 60,834 shares of the biopharmaceutical company’s stock worth $1,147,000 after buying an additional 6,643 shares during the last quarter. Creative Planning increased its position in shares of Juno Therapeutics by 248.8% in the first quarter. Creative Planning now owns 48,016 shares of the biopharmaceutical company’s stock worth $1,065,000 after buying an additional 34,250 shares during the last quarter. Finally, Nisa Investment Advisors LLC bought a new position in shares of Juno Therapeutics during the first quarter worth about $200,000. Hedge funds and other institutional investors own 64.51% of the company’s stock.
Shares of Juno Therapeutics, Inc. (JUNO) traded up 2.79% on Friday, hitting $29.88. The stock had a trading volume of 1,898,914 shares. The firm’s 50-day moving average is $27.95 and its 200-day moving average is $24.15. The company’s market cap is $3.11 billion. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $35.04.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 26.26%. The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter last year, the firm earned ($0.64) earnings per share. The firm’s quarterly revenue was down 22.8% compared to the same quarter last year. On average, analysts expect that Juno Therapeutics, Inc. will post ($2.98) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “California Public Employees Retirement System Sells 3,100 Shares of Juno Therapeutics, Inc. (JUNO)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/05/california-public-employees-retirement-system-sells-3100-shares-of-juno-therapeutics-inc-juno.html.
A number of research analysts have issued reports on JUNO shares. Wedbush reissued a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a report on Tuesday, June 6th. Vetr raised Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 price target for the company in a report on Monday, July 10th. FBR & Co decreased their price target on Juno Therapeutics from $30.00 to $29.00 and set a “mkt perform” rating for the company in a report on Friday, May 5th. Zacks Investment Research raised Juno Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, BTIG Research downgraded Juno Therapeutics from a “neutral” rating to a “sell” rating and boosted their price target for the company from $12.00 to $23.00 in a report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $30.81.
In related news, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $27.00, for a total value of $216,000,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now owns 736,189 shares in the company, valued at $22,085,670. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,041,500 shares of company stock worth $217,230,360. Company insiders own 15.26% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
